Clinical trials: Venous Thromboembolism (VTE)
Venous Thromboembolic Disease, Pulmonary Embolism
CHIPs-VTE Study in Hospitalized Patients With Lung Cancer
Venous thromboembolism (VTE) is a common complication of malignancies, in particular to lung cancer. Patients with lung cancer in surgical and medical departments are at high risk of VTE development.
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism, Deep Venous Thrombosis
- Trial name
- NCT04158973
- Testing
- Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge, Routine VTE prophylaxis in hospital
- Volunteers
- 3,200 people
- Sponsor
- China-Japan Friendship Hospital
Venous Thromboembolism
the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients
To compare the predictive effectiveness of the Caprini risk assessment model, the Padua risk assessment model and the VTE risk assessment in medical patients mentioned in the 2018 edition of the Guidelines for the diagnosis…
- Trial name
- NCT04963374
- Testing
- risk evolution scale
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Venous Thromboembolism
Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS
To assess the real-world safety/effectiveness of Eliquis in Korean venous thromboembolism (VTE) patients and patient characteristics that are associated with bleeding among patients taking Eliquis.
- Trial name
- NCT02546817
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Bristol-Myers Squibb
Thromboembolism
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the efficacy and the safety for HFS.
- Trial name
- NCT00320424
- Testing
- Fondaparinux
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism, Prediction Models
Development and Validation of an Interpretable Machine Learning Model for Predicting Venous Thromboembolism（VTE）in Intensive Care Unit (ICU) Patients
Venous thromboembolism remains a leading cause of preventable mortality in intensive care unit (ICU) patients. Existing risk-stratification tools were developed in general medical populations and lack ICU-specific predictors.
- Trial name
- NCT07596264
- Testing
- no intervention
- Where
- China
- Volunteers
- 12,061 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Venous Thromboembolic Disease
Predictors of Attempted Inferior Vena Cava Filters Retrieval.
The InferiorVena Cava (IVC) with filters has been recommended when there is a contraindication or a failure of anticoagulation. Due to the side effects related to the filters, it is recommended to remove them as soon as possible.
- Trial name
- NCT04846725
- Testing
- Data collection
- Where
- France
- Volunteers
- 356 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to
ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.
Overall, only limited evidence exists regarding the clinical benefit of antithrombotic prophylaxis after laparoscopic surgery for cancer.
- Conditions
- The Primary Study Objective is to Assess the Efficacy and, Safety of Extended 4-week Heparin Prophylaxis Compared to, Prophylaxis Given for 8±2 Days After Planned Laparoscopic, Surgery for Colorectal Cancer.
- Trial name
- PRO-LAPS I (NCT01589146)
- Testing
- Heparin, Low-Molecular-Weight
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University Of Perugia
NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism)
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
This study aims to explore the clinical outcomes of Comprehensive Enhanced Preventive Management (CEPM) combined with an amivantamab-containing treatment regimen in Chinese patients with EGFR-mutated advanced NSCLC.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction
- Trial name
- AmiCARE (NCT07469488)
- Testing
- Enhanced dermatologic management, Enhanced IRR Prophylaxis, Enhanced VTE Prophylaxis (Cohort 1 only)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Venous Thromboembolism (VTE)
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Profile of YKYY033 Injection
A phase 1 study to evaluate the safety and tolerability of a single administration of YKYY033 injection in healthy adult participants
- Trial name
- NCT07786779
- Testing
- YKYY033 Injection
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Achilles Tendon Ruptures, Immobilization
Achilles Tendon Rupture - Intervention With Electrical Stimulation
Acute Achilles tendon rupture (ATR) is an injury that is commonly associated with complications, such as blood clotting, muscle loss and tendon lengthening, all of which affect the long-term outcome and return to sports.
- Conditions
- Achilles Tendon Ruptures, Immobilization, Venous Thromboembolism (VTE), Muscle Atrophy
- Trial name
- C-NMES-ATR (NCT06601088)
- Testing
- Neuromuscular Electrical Stimulation
- Volunteers
- 220 people
- Sponsor
- Karolinska University Hospital
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Venous Thromboembolism, Bleeding
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral factor Xa inhibitor apixaban…
- Trial name
- ARTS (NCT06523959)
- Testing
- Apixaban 2.5 MG
- Where
- Finland
- Volunteers
- 5,436 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
Venous Thromboembolism, Liver Transplantation
Risk Factors and a nOmogram of Venous thromboEmbolism in Patients After liveR Transplantation(ROVER Study)
Liver transplantation is currently an effective treatment for end-stage liver disease. The high incidence of thrombotic related complications in the early postoperative period after orthotopic liver transplantation(OLT) has been…
- Trial name
- NCT05209048
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
Timing of VTE Prophylaxis in TBI
This study compares the efficacy and complication rates of early (24 hours) versus late (72 hours) VTE prophylaxis administration to TBI patients.
- Trial name
- NCT03081169
- Testing
- Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
- Where
- United States
- Sponsor
- Loyola University
Treatment of Venous Thromboembolism
A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database
This is an observational study in which data from the past is collected for a treatment which is already available for doctors to prescribe for venous thromboembolism (VTE).
- Trial name
- NCT04923139
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 2 sites in Japan
- Volunteers
- 2,627 people
- Sponsor
- Bayer
Venous Thromboembolism
Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)
This study was designed to assess the safety and efficacy of GW813893 in the prophylaxis of VTE following TKR and to provide evidence to enable the selection of the appropriate dose(s) and dose regimen of GW813893 for future…
- Trial name
- NCT00541320
- Testing
- GW813893
- Where
- 8 sites in United States
- Sponsor
- GlaxoSmithKline
Thromboembolism
Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER II (NCT00680186)
- Testing
- Warfarin, Dabigatran etexilate
- Where
- 220 sites in United States, Australia and 29 more
- Volunteers
- 2,589 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism (VTE), Cancer
Vortosiran for VTE Prevention
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop…
- Conditions
- Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
- Trial name
- NCT07850453
- Testing
- Vortosiran
- Where
- 30 sites in Bulgaria, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB